Publications, Pharmaceutical

Investigation of Powder Blend Uniformity and Deposition in a Nasal Cast Using a Unit Dose Nasal System

Interest is increasing in the use of powder formulations for nasal deposition for pain relief, disorders of the central nervous systems and vaccination. This article describes an experimental study of the deposition behavior of different blends of sumatriptan, a drug used for the treatment of migraine, with a unit dose nasal drug delivery system. Blends were formulated using different lactose grades, with and without magnesium stearate, and delivered to a validated nasal cast (use courtesy of Aptar Pharma/DTF/Univ. of Tours) using a proprietary unit dose nasal drug delivery system from Aptar Pharma. The results show that despite differences in cohesivity successful deposition was achieved with all model formulations at target sites such as the turbinates and olfactory region. The results demonstrate the potential utility of the unit dose nasal system.

Download Publication
1 Sep 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

18 Sep 2018

Aptar Pharma provides guidance on FDA regulatory framework for OINDPs

Webinars, Pharmaceutical, Innovation & Insights, Market Insights, Product Solutions

Read More
1 Jun 2018

Connected Medicine: Insights from Payers and Other Stakeholders

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Brand Differentiation

Read More
1 Apr 2018

A track record of success for nasal drug delivery in drug repurposing

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Brand Differentiation, Product Solutions

Read More
16 Sep 2016

The Nasal Drug Delivery Journey: from Systemic to Nose-to-Brain?

Webinars, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
1 24 25 26 27
Back To Top